eligibility_summary
Adults ≥18 with aggressive B-cell NHL (DLBCL, tFL, HGBL, PMBL, FL3b), R/R after ≥1 line, mass >4 cm, measurable disease, OS ≥12 w, adequate labs/organ fxn, ineligible/unwilling for HDCT/ASCT, adequate apheresis, PCNSL allowed, secondary CNS not. Exclude: allergy, prior allo-HSCT/organ tx/CAR-T, active HBV/HCV/HIV/TP/CMV/EBV, autoimmune/genetic dz, recent VTE/MI, other cancer <5 y, recent IS/chemo/RT/live vax, pregnancy/no contraception, other trials, poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions and mechanisms: All-trans retinoic acid (ATRA, oral retinoid, RAR/RXR agonist) as chemo-free bridge/maintenance to induce tumor cell differentiation, reduce immunosuppressive myeloid cells (MDSCs/TAMs), and enhance T-cell trafficking, Zanubrutinib (oral covalent BTK inhibitor) to block BCR/BTK→NF-κB/PI3K-AKT signaling, suppressing B-NHL growth and supportive microenvironment, Optional radiotherapy (local ionizing radiation) for debulking and immunogenic antigen release, CAR-T therapy (autologous gene-modified T cells) redirecting cytotoxicity to B-cell antigens on lymphoma, PD-1 inhibitor (IV monoclonal antibody) blocking PD-1/PD-L1 to reverse T-cell/CAR-T exhaustion. Targeted cells/pathways: malignant B cells via BCR/BTK, T-cell/CAR-T activation and PD-1 checkpoint, myeloid suppressors via RAR/RXR, DNA-damage/immunogenic pathways via radiotherapy.